DexCom, Inc.

NasdaqGS DXCM

DexCom, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2024: 40.15

DexCom, Inc. Interest Coverage Ratio is 40.15 for the Trailing 12 Months (TTM) ending September 30, 2024, a 30.70% change year over year. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.

DexCom, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2023 was 30.72, a 345.57% change year over year.
DexCom, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was 6.89, a 84.74% change year over year.
DexCom, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2021 was 3.73, a -10.21% change year over year.
DexCom, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2020 was 4.16, a 294.31% change year over year.

Key data

Date	Interest Coverage Ratio	Debt to Equity Ratio	Interest Expense To Sales	Inventory Turnover Ratio

NasdaqGS: DXCM

DexCom, Inc.

CEO	Mr. Kevin Ronald Sayer
IPO Date	April 14, 2005
Location	United States
Headquarters	6340 Sequence Drive
Employees	9,500
Sector	Healthcare
Industries Telehealth 3D Printing Biotechnology Hardware & Electronics Internet of Things (IoT) Medical Instruments Pharmaceuticals Robotics

Description

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Key trends

Past 5 years